Experts have warned a more tailored approach is needed to the prescribing of statins, following a new study suggesting they are ineffective at lowering cholesterol to target levels in more than half of patients.
The research by primary care experts at The University of Nottingham, which is published in Heart, found that 51.2 per cent of patients prescribed statins saw little benefit to their cholesterol levels within two years, leading to a significant risk of developing cardiovascular disease in the future.
However, the researchers also revealed a significant therapeutic effect for the other 48.8 per cent - statins in this group of patients were not only successful in lowering cholesterol by at least 40 per cent, but were more successful in preventing heart attack, stroke and narrowing of the arteries.
And there were some factors that the researchers were unable to study in detail, for example, how well patients took their medication as prescribed.
As a result, they urged patients not to stop taking their medication.
Dr Stephen Weng, Assistant Professor in Integrated Epidemiology and Data Science, in the University’s Division of Primary Care, led the study with GP researchers.
He said: “Our research has shown that in almost half of patients prescribed statins they are very effective and offer significant protection against cardiovascular disease.
“However, for the other half - whether it’s due to your genetic make-up, having side effects, sticking to the treatment, or other medications – we don’t see that intended benefit.
“We have to develop better ways to understand differences between patients and how we can tailor more effective treatment for those millions of patients who are simply blanket prescribed statins.”
Low-density lipoprotein cholesterol (LDL-C), often referred to as ‘bad cholesterol’, is a well-known risk factor for the hardening and narrowing of the arteries and CVD, which remains the leading cause of death globally.
Statins are the most widely prescribed class of drugs and work by lowering the level of LDL-C in the blood and reduce the production of it inside the liver.
The study looked at the data of more than 165,400 GP patients from the UK Clinical Practice Research Datalink system who had previously been unaffected by CVD before being prescribed statins.
Dr Ralph Akyea, a NIHR-SPCR funded PhD student who conducted the analysis, said: “Based on current national guidelines, a less than 40 per cent reduction in the level of bad cholesterol after two years of taking statins was considered ineffective. Our study revealed that 84,609 (51.2 per cent) had a poor response to the statin treatment and, as a result, many people remained at a much higher risk of CVD caused by a build-up of plaque in their arteries.”
Other factors including the patient’s sex, age, weight, or other conditions have been reported to contribute to the variation in the success of statins reducing bad cholesterol, but the impact is considered by doctors to be modest.
New prediction tools
It’s thought that genetic factors and patients not sticking to their medication may be an important explanation for this phenomenon.
Previous studies have looked at statin use but differences in the way the studies were designed and their data make it difficult to compare what they mean.
As the increasing levels of statin prescribing in the UK follows the same trend in the US and many other countries, the results of the recent study could be applied to other Western populations.
Recent changes to national clinical guidelines to reduce cardiovascular disease have massively increased the number of patients considered suitable for statin therapy. However, there is currently no consideration that some patients might respond better than others.
The Nottingham team are calling for further research into the issue and said that doctors need new tools to help predict patients’ cholesterol response to statins and other drugs. This could help tailor treatments and ensure the best possible outcomes for patients.
Full paper citation: Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease doi 10.1136/heartjnl-2018-314253
— Ends —
Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email firstname.lastname@example.org or see the Globelynx website for how to register for this service.
For up to the minute media alerts, follow us on Twitter
Notes to editors:
The University of Nottingham is a research-intensive university with a proud heritage, consistently ranked among the world's top 100. Studying at the University of Nottingham is a life-changing experience and we pride ourselves on unlocking the potential of our 44,000 students - Nottingham was named both Sports and International University of the Year in the 2019 Times and Sunday Times Good University Guide, was awarded gold in the TEF 2017 and features in the top 20 of all three major UK rankings. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement. We are ranked eighth for research power in the UK according to REF 2014. We have six beacons of research excellence helping to transform lives and change the world; we are also a major employer, proud of our Athena SWAN silver award, and a key industry partner- locally and globally.